March 23, 2021 – Ontada, McKesson’s oncology technology and insights business, announced today that Susan Shiff has joined as President.
In this role, Shiff will continue to build on Ontada’s momentum in delivering real-world insights to transform the fight against cancer, the company said.
As Ontada’s new leader, Shiff will be focused on accelerating business growth by continuing to enhance its world-class suite of oncology provider technologies, while leveraging the business’ deep expertise in oncology insights, data and real-world evidence (RWE) to improve patient outcomes.
Most recently, Shiff was SVP & Head for Merck & Co, Inc.’s Center for Observational and Real-World Evidence. She also helped define the investment strategy for the $500MM Merck Global Health Innovation Fund, including new ventures with digital health companies.
Prior to Merck, Shiff began her career with the Center of Disease Control and Prevention and also worked for life science leaders including Johnson & Johnson, Roche and Pfizer. Shiff holds an M.B.A. from Cornell University and a Ph.D. from the University of California at Los Angeles.
At Ontada, Shiff replaces Derek Rago who had been serving as Interim President for Ontada and led the business through its launch. Rago will remain with McKesson and has been named SVP of strategic initiatives for Ontada.